Stock Track | Boston Scientific Plummets 5.02% Intraday on Lowered Full-Year Guidance Despite Strong Q1 Earnings

Stock Track04-25 00:23

Boston Scientific's stock plummeted 5.02% during intraday trading on Friday, marking a significant decline for the medical device maker.

The sharp drop comes despite the company reporting better-than-expected first-quarter results, with revenue rising 12% year-over-year to $5.203 billion and adjusted EPS reaching $0.80. However, investors reacted negatively to the company's decision to lower its full-year adjusted EPS guidance to a range of $3.34-$3.41. Management cited weaker-than-expected sales in its renal stone treatment devices and Watchman cardiac rhythm products as the primary reasons for the guidance reduction.

The decline appears to be a combination of disappointment over the revised outlook and profit-taking activity following a nearly 9% surge in the previous trading session. While the company maintains a long-term growth orientation with strategic acquisitions as its top capital allocation priority, the mixed signals from strong quarterly performance but reduced annual guidance have prompted this technical correction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123976769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-25 00:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123976769","market":"us","top_or_hot":-1,"title":"Stock Track | Boston Scientific Plummets 5.02% Intraday on Lowered Full-Year Guidance Despite Strong Q1 Earnings","media":"Stock Track","content":"<p>Boston Scientific's stock plummeted 5.02% during intraday trading on Friday, marking a significant decline for the medical device maker.</p><p>The sharp drop comes despite the company reporting better-than-expected first-quarter results, with revenue rising 12% year-over-year to $5.203 billion and adjusted EPS reaching $0.80. However, investors reacted negatively to the company's decision to lower its full-year adjusted EPS guidance to a range of $3.34-$3.41. Management cited weaker-than-expected sales in its renal stone treatment devices and Watchman cardiac rhythm products as the primary reasons for the guidance reduction.</p><p>The decline appears to be a combination of disappointment over the revised outlook and profit-taking activity following a nearly 9% surge in the previous trading session. While the company maintains a long-term growth orientation with strategic acquisitions as its top capital allocation priority, the mixed signals from strong quarterly performance but reduced annual guidance have prompted this technical correction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Boston Scientific Plummets 5.02% Intraday on Lowered Full-Year Guidance Despite Strong Q1 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Boston Scientific Plummets 5.02% Intraday on Lowered Full-Year Guidance Despite Strong Q1 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-25 00:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Boston Scientific's stock plummeted 5.02% during intraday trading on Friday, marking a significant decline for the medical device maker.</p><p>The sharp drop comes despite the company reporting better-than-expected first-quarter results, with revenue rising 12% year-over-year to $5.203 billion and adjusted EPS reaching $0.80. However, investors reacted negatively to the company's decision to lower its full-year adjusted EPS guidance to a range of $3.34-$3.41. Management cited weaker-than-expected sales in its renal stone treatment devices and Watchman cardiac rhythm products as the primary reasons for the guidance reduction.</p><p>The decline appears to be a combination of disappointment over the revised outlook and profit-taking activity following a nearly 9% surge in the previous trading session. While the company maintains a long-term growth orientation with strategic acquisitions as its top capital allocation priority, the mixed signals from strong quarterly performance but reduced annual guidance have prompted this technical correction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1123976769","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123976769","pubTimestamp":1777047796,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Boston Scientific's stock plummeted 5.02% during intraday trading on Friday, marking a significant decline for the medical device maker.The sharp drop comes despite the company reporting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"个股追踪|波士顿科学盘中暴跌5.02%，因下调全年指引，尽管Q1盈利强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"Boston Scientific's stock plummeted 5.02% during intraday trading on Friday, marking a significant decline for the medical device maker.The sharp drop comes despite the company reporting better-than-expected first-quarter results, with revenue rising 12% year-over-year to $5.203 billion and adjusted EPS reaching $0.80. However, investors reacted negatively to the company's decision to lower its full-year adjusted EPS guidance to a range of $3.34-$3.41. Management cited weaker-than-expected sales in its renal stone treatment devices and Watchman cardiac rhythm products as the primary reasons for the guidance reduction.The decline appears to be a combination of disappointment over the revised outlook and profit-taking activity following a nearly 9% surge in the previous trading session. While the company maintains a long-term growth orientation with strategic acquisitions as its top capital allocation priority, the mixed signals from strong quarterly performance but reduced annual guidance have prompted this technical correction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123976769","isCrawlerRequest":true}